Ultra-short immunotherapy before surgery for skin cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a very short course of immunotherapy (nivolumab) before standard surgery for patients with certain types of advanced or hard-to-treat skin cancer (cutaneous squamous cell carcinoma). The goal is to see if this approach can reduce the need for extensive or disfiguring surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of skin cancer called cutaneous squamous cell carcinoma that is linked to sun exposure and is at a stage where extensive or disfiguring surgery is typically needed.
- Your cancer is in specific locations such as the lip, ear, face, scalp, neck, or other body areas (but not the vulva, anus, or penis).
- You are in good enough health to be up and about (WHO performance status 0-2).
- Your blood tests show adequate kidney and liver function, and you have enough red and white blood cells and platelets.
- You have not had prior immunotherapy or systemic cancer treatment for this condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if two immunotherapy drugs, nivolumab and relatlimab, given before surgery can help shrink a type of skin cancer called cutaneous squamous cell carcinoma. It's for people whose cancer can be removed with surgery.
This Phase 2 trial tests pembrolizumab (an immune therapy) given before surgery to see if it can help control high-risk invasive cutaneous squamous cell carcinoma. The goal is to improve outcomes by treating cancer earlier and then following with standard surgery and radiation if needed.
This trial tests if giving a combination of two immunotherapy drugs (nivolumab and relatlimab) before surgery works better than one drug alone for people with large or high-risk basal cell skin cancer that needs surgery. The goal is to shrink the cancer and make surgery easier.
This trial tests whether giving a shorter course of immunotherapy after surgery can help prevent melanoma from coming back. It is for people with high-risk melanoma who have had the cancer fully removed.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (EGFR inhibitor)—given before surgery for locally advanced squamous cell skin cancer. The goal is to shrink the tumor enough to make surgery safer and more effective.
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
Hear when a new Cutaneous Squamous Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.